Loading provider…
Loading provider…
Dermatology Physician in Fremont, CA
NPI: 1326018987Primary Employer
Center for Dermatology Cosmetic & Laser Surgery-Fremont Office
centerforderm.com
HQ Phone
Get MD Sunil's Phone Numberphone_androidMobile
Get MD Sunil's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1984 - 2026
FL State Medical License
1987 - 1998

American Board of Dermatology
Dermatology

American Board of Internal Medicine
Internal Medicine
Mount Sinai Medical Center of Florida, Inc
Residency • Dermatology
1987 - 1990
University of California (San Francisco)/Mount Zion
Residency • Internal Medicine
1983 - 1986
Keck School of Medicine of USC
keck.usc.edu
Medical School
Until 1983
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 719 | 1,229 |
| 2 | 17000Destruction of skin growth | 261 | 391 |
| 3 | 17003Destruction of 2-14 skin growths | 209 | 1,522 |
| 4 | 99212Established patient outpatient visit, total time 10-19 minutes | 206 | 257 |
| 5 | 17110Destruction of up to 14 skin growths | 187 | 268 |
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Cutis
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
Authors: Jeffrey Dover, Emil Tanghetti
Publication Date: 2018-06-08
Lead Sponsor: UK Innovations GP LTD
Collaborators: Lindus Health, Advarra
Intervention / Treatment: DEVICE: STR Skin Tag Removal device with diary and follow-up
Lead Sponsor: ASLAN Pharmaceuticals
Intervention / Treatment: DRUG: Placebo Comparator, BIOLOGICAL: ASLAN004
Lead Sponsor: Takeda
Intervention / Treatment: DRUG: Placebo, DRUG: Apremilast, DRUG: TAK-279